参考文献
［1］RAVANI P, BERTELLI E, GILL S, et al. Clinical trials in minimal change disease [J]. Nephrol Dial Transplant,2017, 32 (suppl_1): i7-i13.
［2］VIVARELLI M, MASSELLA L, RUGGIERO B. Minimal change disease [J]. Clin J Am Soc Nephrol, 2017,12 (2): 332-345.
［3］FLOEGE J, AMANN K. Primary glomerulonephritides [J]. Lancet, 2016, 387 (10032): 2036-2048.
［4］VIVARELLI M, MASSELLA L, RUGGIERO B, et al. Minimal Change Disease [J]. CJASN, 2017, 12 (2): 332-345.
［5］JENNETTE J C, OLSON J L, SILVA F G, et al. Heptinstall′s pathology of the kidney [M]. 7th ed.[S. l.]: Wolters Kluwer, 2015.
［6］RANGANATHAN S. Pathology of Podocytopathies Causing Nephrotic Syndrome in Children [J]. Front Pediatr, 2016, 4: 32.
［7］COLVIN R B, CHANG A, GAUT JP, et al. Diagnostic Pathology: Kidney Diseases [M]. 2nd ed. [S. l.]: Elsevier, 2016.
［8］KARL SKORECKI, CHERTOW G M, PHILIP A. MarsdenBrenner & Rector′s the kidney [M]. 10th ed.[S. l.]: Elsevier, 2016.
［9］FOGO A B, LUSCO M A, NAJAFIAN B, et al. AJKD Atlas of Renal Pathology: Minimal Change Disease [J]. Am J Kidney Dis, 2015, 66 (2): 376-377.
［10］Kidney Disease:(KDIGO) glomerunephritis Work Group. KDIGO Clinical Practice Guidelines for Glomerulonephritis [J]. Kidney Int (Suppl 2), 2012,139-274.
［11］SILIGATO R, CERNARO V, NARDI C, et al. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis [J]. Expert Opin Investig Drugs, 2018, 27 (11): 839-879.
［12］SINHA A, PURASWANI M, KALAIVANI M, et al. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial [J]. Kidney Int, 2019, 95 (1): 210-218.
［13］BRUGNANO R, DEL SORDO R, COVARELLI C, et al. IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis? [J]. J Nephrol, 2016, 29 (4): 479-486.
［14］KHOW K S, YONG A S, YONG T Y, et al. Minimal change disease associated with newly diagnosed mantle cell lymphoma [J]. Renal Fail, 2014, 36 (4): 634-637.
［15］CASALE T B, BURKS A W. Clinical practice. Hymenoptera-sting hypersensitivity [J]. The New England J Med, 2014, 370 (15): 1432-1439.
［16］HU W, CHEN Y, WANG S, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy [J]. CJASN, 2016, 11 (4): 585-592.
［17］BOMBACK A S, MARKOWITZ G S. Lupus Podocytopathy: A Distinct Entity [J]. CJASN, 2016, 11 (4):547-548.
［18］Kidney Disease: Improving Global Outcomes (KDIGO)Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Int Suppl, 2020: 176.